Abbvie Inc (ABBV)

$214.50 +2.20 (1.04%)
Market Cap 375.09B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.98
Forward PE 14.95
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 3,814,054
Avg Vol 6,780,002
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 91%
Beta 0.32
Analysts Strong Sell
Price Target $251.14

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
mebotta10
mebotta10 May. 22 at 2:31 PM
$HCWB breakthroughs with huge potential and a market cap of 17million. Will eat into $ABBV revenue with their autoimmune treatment.
0 · Reply
StockElementCorporation
StockElementCorporation May. 22 at 2:10 PM
Ripping . Did you catch it ? $OSS , $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:46 PM
$SLS GPS BLA for CR1 - I put this together for those who may not have the FULL Understanding. • GPS PH 2 CR1 TRIAL MOS Not Yet Reached > 67.6 months ... is better than transplant. The Share Price will continue climbing until the 80th Event PR and then it will Launch - and then We will see ballistic VERTICALITY on the P3 Top Line Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes. in Count Down Mode. - Event rates are not linear, with follow-up ranging from 25 to 62 months. --- 80th Event may have already occurred, waiting to cycle through the data collection process.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:41 PM
$SLS $LLY $ABBV From the Presentation - xCCO Estimating Minimum Revenue Per Patient for GPS in Year 1. Subsequently - REGAL Clinicians Requested - Continued Dosing Beyond Year 1 Year 2 6 X Per Year Booster Series / $110K Year 3 4 X Per Year Booster Series / $70K
0 · Reply
Loudermilk64
Loudermilk64 May. 22 at 1:39 PM
$ABBV AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C infection (HCV) in adults and children aged 3 years and older. The final European Commission decision is expected in the third quarter of 2026. If approved, MAVIRET would be indicated for both acute and chronic hepatitis C (HCV) infection in the European Union.
0 · Reply
StockElementCorporation
StockElementCorporation May. 22 at 1:36 PM
Trade Plan 5/22 ☀️ $OSS break over 17.04, 20c Jul $ABBV break over 214.5, 220c Jun 18 $MRAM break over 33, looking for shares $AFRM break over 69, 75c Jun 18
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:14 PM
$SLS $LLY $ABBV Gps Immunotherapy is getting the Fda Approval to Treat 100,000 AML patients currently in Remission. The xCCo Estimated $280K Revenue Per Patient Year 1. Indefinite Multi Year Dosing Regime Compounds the Rev. - $28B Total Addressable Market - Right out of the GATE Plus 12,500 AML CR2/3 Patients who are Eligible Each Year ... Just this CR2/3 Market is worth $75 Per Share. TAM - rNPV - Just for CR2/3 - Cr1 is worth 3-4x
0 · Reply
focafoca99
focafoca99 May. 22 at 12:19 PM
$ABBV won a positive CHMP opinion for MAVIRET to treat acute hepatitis C. https://www.rapidticker.com/news/abbv-abbvie-announces-positive-chmp-opinion-8da792
0 · Reply
focafoca99
focafoca99 May. 21 at 10:55 PM
$ABBV disclosed new ASCO 2026 oncology data spanning solid tumors and blood cancers. https://www.rapidticker.com/news/abbv-abbvie-announces-new-data-at-4271c6
0 · Reply
Fosco_
Fosco_ May. 21 at 9:12 PM
$IMMX Some ASCO data is out. This morning layout perfectly anticipated tonight's ASCO abstracts. Regeneron’s Linvoseltamab ($REGN LINKER-AL2) shows solid response but highlights persistent continuous-dosing toxicity risks. AbbVie’s Ententamig ($ABBV) faces standard bispecific multi-dose fatigue. AstraZeneca/Gracell's dual CAR-T (AZD0120) requires heavy logistics/hospitalization constraints. Meanwhile, Immix’s NXC steals the show. An unparalleled 95% Complete Response rate with zero relapses locks in NXC-201 as a true one-and-done outpatient functional cure
1 · Reply
Latest News on ABBV
AbbVie reports positive CHMP opinion for Maviret

2026-05-22T12:12:15.000Z - 2 hours ago

AbbVie reports positive CHMP opinion for Maviret

ABBV

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 3 hours ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

ABBV

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 16 hours ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

ABBV

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

2026-05-21T20:19:37.000Z - 18 hours ago

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

ABBV

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 18 hours ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

ABBV

AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-15T12:51:42.000Z - 7 days ago

AbbVie price target lowered to $235 from $236 at Evercore ISI

ABBV

AbbVie price target raised to $298 from $294 at Piper Sandler

2026-05-14T11:07:12.000Z - 8 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

ABBV

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 8 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

May 9, 2026, 10:08 AM EDT - 13 days ago

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

ABBV

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 14 days ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 16 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

ABBV

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

2026-05-05T12:32:52.000Z - 17 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

ABBV

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 17 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

ABBV IBD

AbbVie price target raised to $236 from $232 at Evercore ISI

2026-05-04T12:13:35.000Z - 18 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

ABBV

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

May 2, 2026, 8:45 AM EDT - 20 days ago

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

ABBV AZN GSK

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 20 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

ABBV

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 21 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

ABBV BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 21 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

ABBV

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T18:00:46.000Z - 21 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

ABBV

AbbVie price target raised to $265 from $262 at Canaccord

2026-04-30T13:31:03.000Z - 22 days ago

AbbVie price target raised to $265 from $262 at Canaccord

ABBV

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 22 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

ABBV

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:15:57.000Z - 22 days ago

AbbVie upgraded to Buy at BofA on durable growth

ABBV

AbbVie upgraded to Buy from Neutral at BofA

2026-04-30T10:14:18.000Z - 22 days ago

AbbVie upgraded to Buy from Neutral at BofA

ABBV

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

Apr 29, 2026, 2:50 PM EDT - 22 days ago

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

ABBV

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:41:09.000Z - 22 days ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

ABBV

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:58.000Z - 22 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

ABBV

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-04-29T16:39:07.000Z - 22 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

ABBV

AbbVie says ‘especially pleased’ with immunology and neuroscience results

2026-04-29T13:25:07.000Z - 23 days ago

AbbVie says ‘especially pleased’ with immunology and neuroscience results

ABBV

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 23 days ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 23 days ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 23 days ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 23 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

ABBV

AbbVie reports Q1 adjusted EPS $2.65, consensus $2.67

2026-04-29T12:15:43.000Z - 23 days ago

AbbVie reports Q1 adjusted EPS $2.65, consensus $2.67

ABBV

AbbVie raises FY26 adjusted EPS view to $14.08-$14.28 from $13.96-$14.16

2026-04-29T12:13:45.000Z - 23 days ago

AbbVie raises FY26 adjusted EPS view to $14.08-$14.28 from $13.96-$14.16

ABBV

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 23 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

ABBV

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 23 days ago

AbbVie Reports First-Quarter 2026 Financial Results

ABBV

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 24 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

ABBV

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 24 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

ABBV

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 25 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

ABBV

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 4 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment

ABBV

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 4 weeks ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

ABBV

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 4 weeks ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

ABBV

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 4 weeks ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

ABBV

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 4 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

ABBV

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 5 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

ABBV

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 5 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

ABBV

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 5 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

ABBV

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

Apr 9, 2026, 2:00 PM EDT - 6 weeks ago

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

ABBV AMCR CVX

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 6 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

ABBV

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 6 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

ABBV

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 6 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

ABBV

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 6 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

ABBV

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 6 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 7 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO ABBV AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 7 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 7 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO ABBV AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 7 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 7 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

ABBV

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

ABBV

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 2 months ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

ABBV

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

ABBV

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

ABBV AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

ABBV

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

ABBV

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

ABBV AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

ABBV

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

ABBV

AbbVie Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Mar 6, 2026, 8:26 AM EST - 2 months ago

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

ABBV GILD V

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

ABBV

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

ABBV

mebotta10
mebotta10 May. 22 at 2:31 PM
$HCWB breakthroughs with huge potential and a market cap of 17million. Will eat into $ABBV revenue with their autoimmune treatment.
0 · Reply
StockElementCorporation
StockElementCorporation May. 22 at 2:10 PM
Ripping . Did you catch it ? $OSS , $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:46 PM
$SLS GPS BLA for CR1 - I put this together for those who may not have the FULL Understanding. • GPS PH 2 CR1 TRIAL MOS Not Yet Reached > 67.6 months ... is better than transplant. The Share Price will continue climbing until the 80th Event PR and then it will Launch - and then We will see ballistic VERTICALITY on the P3 Top Line Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes. in Count Down Mode. - Event rates are not linear, with follow-up ranging from 25 to 62 months. --- 80th Event may have already occurred, waiting to cycle through the data collection process.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:41 PM
$SLS $LLY $ABBV From the Presentation - xCCO Estimating Minimum Revenue Per Patient for GPS in Year 1. Subsequently - REGAL Clinicians Requested - Continued Dosing Beyond Year 1 Year 2 6 X Per Year Booster Series / $110K Year 3 4 X Per Year Booster Series / $70K
0 · Reply
Loudermilk64
Loudermilk64 May. 22 at 1:39 PM
$ABBV AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C infection (HCV) in adults and children aged 3 years and older. The final European Commission decision is expected in the third quarter of 2026. If approved, MAVIRET would be indicated for both acute and chronic hepatitis C (HCV) infection in the European Union.
0 · Reply
StockElementCorporation
StockElementCorporation May. 22 at 1:36 PM
Trade Plan 5/22 ☀️ $OSS break over 17.04, 20c Jul $ABBV break over 214.5, 220c Jun 18 $MRAM break over 33, looking for shares $AFRM break over 69, 75c Jun 18
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:14 PM
$SLS $LLY $ABBV Gps Immunotherapy is getting the Fda Approval to Treat 100,000 AML patients currently in Remission. The xCCo Estimated $280K Revenue Per Patient Year 1. Indefinite Multi Year Dosing Regime Compounds the Rev. - $28B Total Addressable Market - Right out of the GATE Plus 12,500 AML CR2/3 Patients who are Eligible Each Year ... Just this CR2/3 Market is worth $75 Per Share. TAM - rNPV - Just for CR2/3 - Cr1 is worth 3-4x
0 · Reply
focafoca99
focafoca99 May. 22 at 12:19 PM
$ABBV won a positive CHMP opinion for MAVIRET to treat acute hepatitis C. https://www.rapidticker.com/news/abbv-abbvie-announces-positive-chmp-opinion-8da792
0 · Reply
focafoca99
focafoca99 May. 21 at 10:55 PM
$ABBV disclosed new ASCO 2026 oncology data spanning solid tumors and blood cancers. https://www.rapidticker.com/news/abbv-abbvie-announces-new-data-at-4271c6
0 · Reply
Fosco_
Fosco_ May. 21 at 9:12 PM
$IMMX Some ASCO data is out. This morning layout perfectly anticipated tonight's ASCO abstracts. Regeneron’s Linvoseltamab ($REGN LINKER-AL2) shows solid response but highlights persistent continuous-dosing toxicity risks. AbbVie’s Ententamig ($ABBV) faces standard bispecific multi-dose fatigue. AstraZeneca/Gracell's dual CAR-T (AZD0120) requires heavy logistics/hospitalization constraints. Meanwhile, Immix’s NXC steals the show. An unparalleled 95% Complete Response rate with zero relapses locks in NXC-201 as a true one-and-done outpatient functional cure
1 · Reply
focafoca99
focafoca99 May. 21 at 8:53 PM
$ABBV rallies on positive CHMP opinion for Boey in Europe. https://www.rapidticker.com/news/abbv-allergan-aesthetics-receives-positive-chmp-23cd11
0 · Reply
Blockwave1
Blockwave1 May. 21 at 8:35 PM
Just THIS WEEK I gave YOU ALL over 2,799% in GAINS for COMPLETELY FREE..(STOCKSWITS)🔥 I GAVE YOU $IBM 22 MAY 26 $240 CALL FOR 1,171% 🥰 I GAVE YOU $HD 22 MAY 26 $415 CALL FOR 400% 🥰 I GAVE YOU $IBM 29 MAY 26 $245 CALL FOR 400% 🥰 I GAVE YOU $AAPL 22 MAY 26 $300 CALL FOR 263% 🥰 I GAVE YOU $COST 22 MAY 26 $1,120 CALL FOR 203% 🥰 I GAVE YOU $COST 22 MAY 26 $1,110 CALL FOR 201% 🥰 I GAVE YOU $ABBV 22 MAY 26 $222.5 CALL FOR 156% 🥰 Turn on post notifications on STOCKWITS🔥 Feel free to join the telegram channel🤙
1 · Reply
Blockwave1
Blockwave1 May. 21 at 8:21 PM
$ABBV 🔥 $222.5 22 MAY 26 (W) CALL 100 $0.23 ➡️ $0.59 🔥 156% GAINER! 🔥 To the moon🤙🚀
0 · Reply
luckyfreedom
luckyfreedom May. 21 at 6:58 PM
$COSM I am still here - just waiting for next the base. I got stopped out on my initial entry. By the way - This is not my priority investment, my time is valuable. Someone couldn’t pay me enough to post here all day long like you Jim. Other stocks I took positions on this morning: $MP $ABBV $HOOD $ANET
1 · Reply
nlrmandate
nlrmandate May. 21 at 6:27 PM
$VKTX I've always favored $ABBV over $NVO as a buyer of Viking. However, with today's Retatrutide trial results, I actually think a BO by NVO has become MORE likely for Viking. With NVO's recent performance, it seems fairly clear that the market views NVO as yesterday's news. It can't buy Reta because LLY won't sell and because Reta isn't very tolerable as a general weight loss drug anyway (as opposed to perhaps a niche player for morbid obesity/bodybuilding). BUT, what it can do is buy the company with THE ONLY REMAINING clinical weight loss asset with the chops to challenge BOTH Terz and Reta....and that would be Viking. I still personally hope it's ABBV that buys Viking, but they need to make a move before NVO wises up and beats them to the punch! And don't think NVO can't afford Viking; from where I sit, they can't afford NOT to BO Viking! Long and insanely
5 · Reply
mebotta10
mebotta10 May. 21 at 5:34 PM
$HCWB $ABBV is cooked!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 8:13 PM
$SLS Always nice to see a new 52 week / 5 year HIGH while waiting for Phase 3 Trial Results. $ABBV $BMY $RHHBY Know GPs is preventing relapse and Extending survival, doing what its done in ALL Previous Trials and is the only reason we are waiting for Near Miraculous Survival Data - they Own the BAT / Aza +VEN - Aza VEN Recently FAILED 3 Large Phase 3 trials conducted by $ABBV - Including 2 for AML Remission Maintenance.
0 · Reply
BillionerOfKing
BillionerOfKing May. 20 at 5:40 PM
$ABBV Current Stock Price: $212.99 Contracts to trade: $212.5 ABBV May 22 2026 Call Entry: $1.99 Exit: $3.56 ROI: 79% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 5:21 PM
$SLS Must really Gobble SCHLONG being short here now, knowing the 80th EVENT IS COMING and and their Short Lies are worn thin. - 80th EVEN PR WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....
1 · Reply
OnTheBalance
OnTheBalance May. 20 at 5:00 PM
$SLS $LLY $ABBV The 80th Event is NOW Around the Corner.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 4:51 PM
$SLS The Share Price will continue climbing until the 80th Event PR and then it will Launch - and then We will see ballistic VERTICALITY on the P3 Top Line Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes. in Count Down Mode. - Event rates are not linear, with follow-up ranging from 25 to 62 months. --- 80th Event may have already occurred, waiting to cycle through the data collection process.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 3:59 PM
$SLS Must really Suck A** being short here now, knowing the 80th EVENT IS COMING and WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....
0 · Reply